Alzheimer's disease and related dementias: From risk factors to disease pathogenesis

It is an exciting time to be a dementia researcher. Although the accelerated approval of aducanumab by the Food and Drug Administration in the United States was controversial in the scientific community (Rabinovici, 2021), there has been more optimism around the September 2022 announcement from Eisai and Biogen that their amyloid beta-lowering antibody lecanemab slows cognitive decline in a Phase 3 clinical trial. Although we will have to wait to see the data for confirmation, scientists have greeted this announcement with cautious excitement as the companies report slowing of cognitive and functional decline by almost 30%. Despite these potentially large successes giving hope for disease-modifying treatments for Alzheimer’s disease (AD), we still have a long way to go. Amyloid-directed therapeutics will be most effective at very early disease stages, before symptom onset, making the need for biomarkers of early disease even more pressing. Thus, a deeper understanding of disease mechanisms beyond amyloid, as well as how risk factors change the brain to cause disease, is needed to develop effective diseasemodifying therapeutics or preventative strategies. In this special issue of the European Journal of Neuroscience, we present a collection of original research papers and reviews addressing these knowledge gaps. These range from fundamental studies of disease mechanisms in animal and cell model systems to studies on human cognition and biomarkers associated with age and disease.

• Publication year

  2022

• Venue

  European Journal of Neuroscience

• Publication date

  2022-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ejn.15857PMID 36324230
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exploring electrophysiological markers of auditory predictive processes and pathological ageing in adults with Down's syndrome

  2022cited by this paper
• Targeting the immune system towards novel therapeutic avenues to fight brain aging and neurodegeneration

  2022cited by this paper
• Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease

  2022cited by this paper
• Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease

  2022cited by this paper
• Electrophysiological alterations of the Purkinje cells and deep cerebellar neurons in a mouse model of Alzheimer disease (electrophysiology on cerebellum of AD mice)

  2022cited by this paper
• From synapses to circuits and back: Bridging levels of understanding in animal models of Alzheimer's disease

  2022cited by this paper
• Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review

  2022cited by this paper
• Diverse pathways to neuronal necroptosis in Alzheimer's disease

  2022cited by this paper
• Exploration of salient risk factors involved in mild cognitive impairment

  2022cited by this paper
• A multi‐hit hypothesis for an APOE4‐dependent pathophysiological state

  2022cited by this paper
• Cognitive functioning, cerebrospinal fluid Alzheimer's disease biomarkers and cerebral glucose metabolism in late‐onset epilepsy of unknown aetiology: A prospective study

  2022cited by this paper
• Altered amyloid precursor protein, tau‐regulatory proteins, neuronal numbers and behaviour, but no tau pathology, synaptic and inflammatory changes or memory deficits, at 1 month following repetitive mild traumatic brain injury

  2022cited by this paper
• Mechanistic and therapeutic implications of EphA‐4 receptor tyrosine kinase in the pathogenesis of Alzheimer's disease

  2022cited by this paper
• Role of proline‐rich tyrosine kinase 2 (Pyk2) in the pathogenesis of Alzheimer's disease

  2021cited by this paper
• Exploration of salient risk factors involved in mild cognitive impairment

  2021cited by this paper
• The role of extracellular matrix alterations in mediating astrocyte damage and pericyte dysfunction in Alzheimer's disease: A comprehensive review

  2021cited by this paper
• Potential neurobiological links between social isolation and Alzheimer's disease risk

  2021cited by this paper
• Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.

  2021cited by this paper
• Factors associated with dropout in the longitudinal Vogel study of cognitive decline

  2021cited by this paper
• Longitudinal changes in behaviour, mood and functional capacity in the primary progressive aphasia variants

  2021cited by this paper
• Therapeutic effects of carvacrol on beta‐amyloid‐induced impairments in in vitro and in vivo models of Alzheimer's disease

  2021cited by this paper
• Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

  2020cited by this paper
• A comparison of blood and brain‐derived ageing and inflammation‐related DNA methylation signatures and their association with microglial burdens

  2020cited by this paper
• A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T)

  2010cited by this paper

• No citing papers are available for this paper.